Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 06 01; 26(11):2506-2514.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carcinoma, Renal Cell
Female
Follow-Up Studies
Humans
Kidney Neoplasms
Longitudinal Studies
Male
Middle Aged
Patient Reported Outcome Measures
Quality of Life
Survival Rate

authors with profiles

Walter M. Stadler